PUBLIC COMPANY
saveHENGRUI PHARMA
USupdated 5mo ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Unknown
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- Treasury sweeps biotech into proposed COINS Act restrictions, but spares Big Pharma’s China licensing dealsDespite the sweeping scope of the ban covering various types of drug molecules, biopharma business development teams can breathe a measured sigh of relief.fiercebiotech · 9d ago
- ESMO: GSK cancer R&D chief says mo-rez data ‘reinforces our belief’ in ADC as phase 3 push ramps upGSK’s cancer R&D chief has suggested the latest slice of early-stage data on its B7-H4-directed antibody-drug conjugate (ADC) has “reinforce[d] our belief in the asset,” as the therapy races throug…fiercebiotech · 10d ago
- Lilly puts $1.1B on the line for Hong Kong biotech’s AI drug delivery platformMETiS TechBio’s AiLNP platform uses machine learning models to develop lipid nanoparticles with potentially better tissue specificity that could enhance a drug’s therapeutic performance.biospace · 11d ago
- Viatris boosts pain drug portfolio with $1.7B buyout of PaciraThe deal hands Viatris two non-opioid pain treatments that booked nearly $700 million in 2025 but could soon lose patent protection. Viatris vowed to use its “intellectual property expertise” to su…biopharma_dive · 23d ago
- Kailera, Hengrui’s GLP-1/GIP candidate delivers weight, menstrual benefits to women with PMOSKailera Therapeutics and Hengrui Pharma’s weekly injection showed benefits beyond weight loss in a mid-stage trial, leading to more regular menstrual cycles in patients with polyendocrine metabolic…biospace · 29d ago
- Lilly sets up next-gen obesity battle with full phase 3 retatrutide dataEli Lilly has shared detailed data from a phase 3 retatrutide trial, revealing that more than one-third of patients on the top dose of the triple-G drug candidate lost at least 25% of their body we…fiercebiotech · 1mo ago
- Novo to pay Hengrui up to $2.6B for a once-weekly obesity pillThe deal, which hands Novo a challenger to Lilly’s market-leading Zepbound, comes as the Danish drugmaker looks to calm investor fears about its future.biopharma_dive · 1mo ago
- STAT+: AstraZeneca invests $2 billion in Summit TherapeuticsAstraZeneca is teaming up with Summit Therapeutics to test its PD-1/VEGF bispecific ivonescimab alongside AstraZeneca’s antibody-drug conjugates.stat · 1mo ago
- STAT+: Pharmalittle: We’re reading about Novo licensing a Chinese obesity pill, Merck pulling an antibiotic, and moreNovo has agreed to pay up to $2.6 billion to license an experimental, weekly weight loss pill from China’s Hengrui Pharmastat · 1mo ago
- Novo adds long-term obesity differentiation in up to $2.6B Hengrui dealInvestors looking for more transformative business development at Novo will have to wait, but a new partnership with China’s Hengrui Pharma adds a new weekly oral option to the Danish pharma’s earl…biospace · 1mo ago
comments(0)
5-min edit window · permanent after that